Skip to content
WorldBrand.AI

Frontier Biotechnologies

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2024

    11 Consecutive Years of Losses and Delayed Annual Report; Channel Inventory Buildup and Revenue Cut Draw Inquiry

    Frontier Biotech's anti-HIV new drug Aikening has fallen short of commercialization expectations; the company has posted losses for 11 consecutive years and delayed disclosure of its 2025 annual report. Because distributor sell-through was below expectations, it reduced revenue by 20.28 million yuan, and the Shanghai Stock Exchange questioned its revenue recognition and channel inventory. It had previously terminated multiple fundraising-backed projects and sold a loss-making subsidiary. Regulatory inquiry.

    Source